Last reviewed · How we verify

eN-Lac® — Competitive Intelligence Brief

eN-Lac® (eN-Lac®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron-binding protein. Area: Infectious Diseases.

phase 3 Iron-binding protein Lactoferrin Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

eN-Lac® (eN-Lac®) — GenMont Biotech Incorporation. eN-Lac is a recombinant human lactoferrin used to treat various infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
eN-Lac® TARGET eN-Lac® GenMont Biotech Incorporation phase 3 Iron-binding protein Lactoferrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron-binding protein class)

  1. GenMont Biotech Incorporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). eN-Lac® — Competitive Intelligence Brief. https://druglandscape.com/ci/en-lac. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: